NeuroSearch will make a presentation at the 29th Cowen and Company Annual
Health Care Conference to be held 16 - 19 March in Boston at the Boston
Marriott Copley Place hotel.

NeuroSearch's presentation is scheduled for:
Tuesday, 17 March at 3:10 p.m. - 3:45 p.m. local time
and will be held by CEO Flemming Pedersen.

The presentation will be webcasted and the link to access the audio webcast
will be available at www.neurosearch.com together with the powerpoint
presentation just before the presentation will be held at the conference.


Contact person:
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4017 5103



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The company's core business covers the development of novel
drugs, based on a broad and well-established drug discovery platform focusing
on ion channels and CNS disorders. A substantial share of NeuroSearch's
activities is partner financed through an alliance with Eli Lilly and Company
and collaborations with GlaxoSmithKline and Abbott. The drug pipeline comprises
8 clinical (Phase I-III) development programmes: ACR16 for Huntington's disease
(Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase
II) in partnership with Abbott, ACR325 for Parkinson's disease (Phase II
ready), ABT-107 and ABT-560 for the treatment of various CNS disorders - both
(Phase I) in collaboration with Abbott, ACR343 for schizophrenia (Phase II
ready) and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch
has a broad portfolio of preclinical drug candidates and holds equity interests
in several biotech companies.

presse.03-09 - cowen annual helth care conference - uk.pdf